Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria

NCT04042402 is registered in ClinicalTrials.gov with Dicerna Pharmaceuticals, Inc., a Novo Nordisk company as lead sponsor.

NCT NCT04042402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04042402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 9, 2019
Completion date
April 1, 2030
Enrollment
75 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

genetic disease, kidney diseases, primary hyperoxaluria type 1 (ph1), primary hyperoxaluria type 2 (ph2), primary hyperoxaluria type 3 (ph3), urologic diseases